Skip to content
Home
About
Story of iCoat Medical
Board of directors
Management
Transplantation
Kidney transplantation
The purpose of TUM012
Ischemia / Reperfusion injury
The kidney transplant market
Key publications
Development
TUM012&TUM020
Pipeline
News
Contact
iCoat Medical
Home
About
Story of iCoat Medical
Board of directors
Management
Transplantation
Kidney transplantation
The purpose of TUM012
Ischemia / Reperfusion injury
The kidney transplant market
Key publications
Development
TUM012&TUM020
Pipeline
News
Contact
NOTICE OF ANNUAL GENERAL MEETING IN ICOAT MEDICAL AB (PUBL)
Julia Ledenstam
-
12:27
The shareholders in iCoat Medical AB (publ), corporate registration number 559172-8208 (the “Company”) are hereby convened […]
read more
iCoat Medical publishes Annual Report 2021
Julia Ledenstam
-
13:02
Press release 16 May 2022 iCoat Medical publishes Annual Report 2021. iCoat Medical today publishes its […]
read more
Göran Lerenius joins iCoat Medical as General Counsel
Julia Ledenstam
-
17:21
Today, iCoat Medical welcomes Göran Lerenius as its General Counsel. As iCoat Medical is progressing its […]
read more
iCoat Medical’s Chief Medical Officer Alireza Biglarnia featured in article from Njurfonden
Julia Ledenstam
-
12:17
On April 19th, Njurfonden published an interview with iCoat Medical’s Chief Medical Officer Alireza Biglarnia highlighting […]
read more
The European Commission has granted iCoat Medical Orphan Drug Designation for TUM012 in the EU
Julia Ledenstam
-
18:46
Today, iCoat Medical announces that the European Commission has issued a positive decision on the company’s […]
read more
Jacob Westman joins iCoat Medical as Head of CMC
Julia Ledenstam
-
08:39
Today, iCoat Medical welcomes Jacob Westman as its Head of Chemistry, Manufacturing and Controls on a […]
read more
Mattias Springare joins iCoat Medical as CFO and Head of Investor Relations
Julia Ledenstam
-
20:15
Today, iCoat Medical welcomes Mattias Springare as its incoming Chief Financial Officer and Head of Investor […]
read more
iCoat Medical receives approval from the Swedish MPA and starts its First in Human trial at Skåne University Hospital
Julia Ledenstam
-
16:09
The Swedish MPA conducted an on-site visit at Skåne University Hospital in December, the facilities were […]
read more
Communiqué from iCoat Medical’s (PUBL) extraordinary general meeting 15 December 2021
Julia Ledenstam
-
19:36
The extra general meeting in iCoat Medical AB (publ), corp. reg. no 559172-8208 (the “Company”) was […]
read more
iCoat Medical to present at ABGSC Private Companies Seminar on December 6
Julia Ledenstam
-
12:47
December 3, 2021 iCoat Medical AB’s CEO, Peder Waern, and CMO, Alireza Biglarnia, will present at […]
read more
Posts navigation
Page
1
Page
2
Posts navigation
older posts